It is hypothesized that tumor cells in the bone lead to increased expression of RANKL on osteoblasts and their precursors. RANKL is an essential mediator of osteoclast function, formation and ...

[140] Denosumab appears to have little toxicity ... Bone disease is a hallmark of multiple myeloma (MM), associated with bone pain, pathological fractures requiring surgery and/or radiation ...

Get detailed information on Denosumab, including pronunciation ... rheumatoid arthritis, multiple myeloma and giant cell tumor of bone. • Caution should be exercised in patients with history ...

The US regulator has approved a new use for Amgen’s blockbuster bone drug Xgeva, to prevent fractures in patients with newly-diagnosed multiple myeloma with bone metastases. Xgeva (denosumab ...

Amgen sells RANKL inhibitor denosumab as Prolia for osteoporosis ... including bone metastases associated with solid tumours and multiple myeloma, giant cell tumours of the bone, and ...

Biosimilars are reducing healthcare costs and improving patient access, with over 60 FDA-approved products across multiple therapeutic areas. Denosumab biosimilars in oncology could save up to $ ...